1. Introduction {#s1}
===============

Ulcerative colitis \[UC\] is a chronic inflammatory bowel disease characterised by recurring episodes of inflammation primarily involving the mucosal layer and occasionally the submucosa of the colon. UC is characterised by clinical symptoms such as rectal bleeding, persistent bloody diarrhoea, and abdominal cramping. The effectiveness of UC therapies is assessed by improvement of these clinical symptoms and mucosal inflammation. Recently, among these therapeutic endpoints, achieving mucosal healing has been recognised as the most important therapeutic goal for UC. Mucosal healing leads to sustained clinical remission in the long term, and it decreases the need for corticosteroids, hospitalisation rates, risk of colorectal cancer, and risk of colectomy.^[@CIT0001],[@CIT0002]^ Although there is no validated definition of mucosal healing, an international organisation of inflammatory bowel disease task forces defined mucosal healing as the absence of friability, blood, erosions, or ulcers in the colonic mucosa.^[@CIT0001]^ However, mucosal healing is often defined as a Mayo endoscopic subscore ≤ 1, which includes erythema and mild friability in recent clinical studies.^[@CIT0003]^ Because erythema and mild friability indicate an inflammatory condition, the Mayo endoscopic subscore ≤ 1 does not always mean an inactive condition of the colonic mucosa that should be called healing. Actually, some reports have suggested that the relapse rate of patients who achieved complete mucosal healing \[defined as a Mayo endoscopic subscore of 0\] was lower than that of patients who achieved only mucosal healing \[defined as a Mayo endoscopic subscore of 1\].^[@CIT0003],[@CIT0004],[@CIT0005]^ Thus, the desired therapeutic goal in UC is complete mucosal healing \[defined as a Mayo endoscopic subscore of 0\] rather than mucosal healing \[defined as a Mayo endoscopic subscore ≤ 1\]. However, potent therapeutic options that induce complete mucosal healing remain to be established.

Budesonide foam is a rectal preparation that has been used since 2006 in Europe \[2-mg/dose of rectal foam; Budenofalk^®^\] and it was newly approved in the USA in October 2014 \[2mg of rectal foam; Uceris^®^\]. Budesonide is a high-potency corticosteroid with a low systemic effect compared with classical corticosteroids. Because of its safety profile, budesonide agents are preferred used as early treatment for UC and Crohn's disease rather than classic corticosteroids such as prednisolone.^[@CIT0006],[@CIT0007],[@CIT0008]^ The recommended dosage of budesonide 2-mg foam for clinical remission has been determined as once-daily \[QD\] administration in Europe or twice-daily \[BID\] administration for 2 weeks followed by QD administration for 4 weeks in the USA. However, its optimal dose for complete mucosal healing remains to be determined.

In this study, we performed a Phase 2 trial to explore the efficacy and safety of once- and twice-daily budesonide foam treatment in Japanese patients and to determine its optimal dose to induce complete mucosal healing.

Materials and Methods {#s2}
=====================

2.1. Study design {#s3}
-----------------

The present trial consisted of run-in and treatment phases. The run-in phase was a single-blind phase for a week before the treatment phase started. The run-in phase aimed to reduce the placebo effect following the double-blind treatment phase. Patients whose symptoms improved during the run-in phase were excluded from the treatment phase. The treatment phase was a double-blind study period for 6 weeks starting with randomisation in a 1:1:1 ratio to three groups administered with QD or BID budesonide foam, or placebo foam. Randomisation was performed using a block size of six with a randomisation programme. Patients were dynamically allocated with the minimisation method to each group based on the following randomisation factors: the total stool frequency subscore; rectal bleeding subscore; endoscopic subscore at baseline \[3--4 or 5--6\]; duration of induction therapy in the present active phase \[\< 4 weeks or ≥4 weeks\]; and extent of the lesion \[proctitis or sigmoiditis\]. BID administration was performed using placebo foam in the placebo group and budesonide foam \[2mg/25 ml\] in the BID group. In the QD group, placebo foam was administered in the morning, and budesonide foam \[2mg/25 ml\] was administered in the evening. All patients, investigators, and funders were blinded until all observations, evaluations, and data collection were completed, and the prespecified statistical analysis plans were finalised.

2.2. Patients {#s4}
-------------

This multicentre, randomised, double-blind, placebo-controlled trial was conducted at 40 centres in Japan between September 2012 and December 2013. The clinical trial was conducted according to good clinical practice. The protocol was approved by the institutional review board for each centre. All patients provided written informed consent. Eligible patients were aged 16--69 years with active, mild to moderate UC. The disease activity for each patient was assessed using a Modified Mayo Disease Activity Index \[MMDAI\] score. A modification was made to the original Mayo Index---friability was deleted from the definition of an endoscopic subscore of 1.^[@CIT0009]^ The enrolment criteria were as follows: an endoscopic subscore of 2; rectal bleeding subscore of 1 or 2; stool frequency subscore of 0--2; lesions restricted to the segment from the rectum to the sigmoid colon; and 12 weeks or longer since the confirmed diagnosis of UC. Oral 5-aminosalicylic acid \[5-ASA\] agents, or oral salazosulfapyridine agents, or probiotics were permitted at stable doses as concomitant therapies. The use of the following drugs and therapies was prohibited during this study: rectal preparations or suppositories of 5-ASA; suppositories of salazosulfapyridine; corticosteroid preparations; cytapheresis; immunomodulators; anti-tumour necrosis factor antibody preparations; and surgical treatment for UC. Patients were excluded from enrolment in this study if they had any of the following: a history of colon resection; irritable bowel syndrome; intolerance or allergic reaction to budesonide; or a plasma cortisol level \< 4.0 μg/dl.

2.3. Efficacy evaluations {#s5}
-------------------------

Patients were evaluated at Weeks 0 \[baseline\], 2, 4, and 6, or at the withdrawal visit. The MMDAI score was assessed at Weeks 0 and 6 by colonoscopy and symptom-recording diary data based on the 3 days closest to each visit. Endoscopic examination was performed by total colonoscopy at Week 0 and total colonoscopy or sigmoidoscopy at Week 6. The endoscopic subscoring by the attending investigator was applied to the analysis data. In addition, the endoscopic subscores were also evaluated by the central committee for endoscopic evaluation, to assure the reliability of the evaluation by the investigators. All evaluations were blindly performed. Complete mucosal healing was defined as an endoscopic subscore of 0. Clinical remission was defined as a rectal bleeding subscore of 0 and endoscopic subscore ≤ 1, and a stool frequency subscore of 0 or a decrease of ≥ 1 in the stool frequency subscore from baseline.

2.4. Safety and acceptance evaluations {#s6}
--------------------------------------

At each visit, the vital signs were measured, adverse effects were assessed, concomitant therapy was reviewed, and a general laboratory test was performed. Morning plasma cortisol level tests were performed at baseline and Week 6. If adverse events did not resolve by Week 6 or the withdrawal visit, a follow-up survey was administered until the adverse events disappeared. To assess patients' acceptance at Week 6 or the withdrawal visit, all patients were asked to answer questionnaires about general problems related to the treatment. If patients had experience of using any other enemas, they were requested to answer another questionnaire to compare the other enemas.

2.5. Sample size {#s7}
----------------

We referred to the results of a late phase 2 study of budesonide rectal foam in European UC patients \[unpublished data\]. The estimated percentage of clinical remission in the twice-daily budesonide foam group was 38.7%. With an estimated drop-out rate of 10%, we aimed to include 55 patients in each group and 165 patients in total. It was possible to calculate the clinical remission rate with an accuracy of ± 13.5%. The target sample size was considered acceptable for the objective of exploring the efficacy in each group.

2.6. Statistical methods {#s8}
------------------------

The demographics and baseline characteristics of patients in this trial were summarised to assess the balance of the three treatment groups by descriptive statistics. The efficacy analysis was performed in the full analysis set consisting of all patients who were enrolled, randomised, received at least one dose of study treatment, and had at least one available efficacy datum. The safety analysis was performed in the safety analysis set consisting of all patients who were enrolled, randomised, and received at least one dose of study treatment.

Efficacy analysis was performed using the logistic regression model, after adjusting for the sum of three MMDAI subscores consisting of: the endoscopic subscore, rectal bleeding subscore, and stool frequency subscore \[3--4 or 5--7\] at baseline; extent of the lesion \[proctitis or sigmoiditis\]; and period of present induction therapy \[≤ 27 days or ≥ 28 days\] to compare the clinical response among treatment groups. To evaluate the percentage of complete mucosal healing, the Cochran-Mantel-Haenszel test, a comparison between the BID and QD groups, and subgroup analysis were performed in post hoc analyses. All statistical tests were conducted at a two-tailed level of significance of 0.05. No adjustment was made for multiple comparisons because the analysis should be considered exploratory.

3. Results {#s9}
==========

3.1. Patient disposition, baseline demographics, and clinical characteristics {#s10}
-----------------------------------------------------------------------------

The disposition of patients is shown in [Figure 1](#F1){ref-type="fig"}. Of 229 patients who gave informed consent, 54 were not enrolled in the single-blind run-in phase. Among the remaining 175 patients, 165 were randomised to the double-blind treatment phase; 158 patients completed the study treatments. All 165 patients were included in the full analysis set for efficacy and safety assessment. Baseline demographics and clinical characteristics were generally balanced among the three randomised groups \[[Table 1](#T1){ref-type="table"}\].

![Patient flow diagram. BID, twice a day; QD, once daily.](eccojc_jjv208_f0001){#F1}

###### 

Baseline demographics and clinical characteristics

                                                           Placebo \[*N* = 54\]   Budesonide foam QD \[*N* = 55\]   Budesonide foam BID \[*N* = 56\]   Total \[*N* = 165\]
  -------------------------------------------------------- ---------------------- --------------------------------- ---------------------------------- ---------------------
  Age \[years\], mean \[SD\]                               39.9 \[13.0\]          44.7 \[13.3\]                     40.8 \[11.2\]                      41.8 \[12.6\]
  Male sex, *n* \[%\]                                      31 \[57.4\]            32 \[58.2\]                       26 \[46.4\]                        89 \[53.9\]
  Body weight \[kg\], mean \[SD\]                          61.7 \[10.3\]          60.7 \[13.7\]                     60.1 \[11.5\]                      60.8 \[11.9\]
  Current smoker, *n* \[%\]                                3 \[5.6\]              1 \[1.8\]                         5 \[8.9\]                          9 \[5.5\]
  Duration of disease \[years\], mean \[SD\]               3.5 \[3.5\]            5.7 \[5.6\]                       5.8 \[5.9\]                        5.0 \[5.2\]
  Clinical course, *n* \[%\]                                                                                                                           
   First attack                                            8 \[14.8\]             6 \[10.9\]                        9 \[16.1\]                         23 \[13.9\]
   Relapsing/remitting                                     46 \[85.2\]            49 \[89.1\]                       47 \[83.9\]                        142 \[86.1\]
  Duration of present active phase \[days\], mean \[SD\]   108.9 \[202.4\]        86.0 \[131.3\]                    95.3 \[140.4\]                     96.6 \[160.0\]
   \<4 weeks, *n* \[%\]                                    22 \[40.7\]            27 \[49.1\]                       27 \[48.2\]                        76 \[46.1\]
   ≥4 weeks, *n* \[%\]                                     32 \[59.3\]            28 \[50.9\]                       29 \[51.8\]                        89 \[53.9\]
  Extent of lesions, *n* \[%\]                                                                                                                         
   Proctitis                                               25 \[46.3\]            26 \[47.3\]                       28 \[50.0\]                        79 \[47.9\]
   Sigmoiditis                                             29 \[53.7\]            29 \[52.7\]                       28 \[50.0\]                        86 \[52.1\]
  MMDAI, *n* \[%\]                                                                                                                                     
   Score 3--5                                              27 \[50.0\]            26 \[47.3\]                       25 \[44.6\]                        78 \[47.3\]
   Score 6--8                                              27 \[50.0\]            29 \[52.7\]                       31 \[55.4\]                        87 \[52.7\]
  Previous medication for UC --- *n* \[%\]                                                                                                             
   Oral 5-ASA                                              47\[87.0\]             48\[87.3\]                        44\[78.6\]                         139\[84.2\]
   5-ASA enema or suppository                              21\[38.9\]             23\[41.8\]                        25\[44.6\]                         69\[41.8\]
  Concomitant therapy for UC--- *n* \[%\]                                                                                                              
   Oral 5-ASA                                              47 \[87.0\]            48 \[87.3\]                       43 \[76.8\]                        138 \[83.6\]
   Oral salazosulfapyridine                                0 \[0.0\]              0 \[0.0\]                         1 \[1.8\]                          1 \[0.6\]
   None                                                    7 \[13.0\]             7 \[12.7\]                        12 \[21.4\]                        26 \[15.8\]

MMDAI, Modified Mayo Disease Activity Index; BID, twice a day administration; QD, once daily administration; SD, standard deviation, 5-ASA, 5-aminosalicylic acid; UC, ulcerative colitis.

3.2. Efficacy {#s11}
-------------

### 3.2.1. Complete mucosal healing {#s12}

The percentages of patients achieving complete mucosal healing in the budesonide foam BID and QD groups were significantly greater than that in the placebo foam group (46.6%, odds ratio \[OR\] 15.553, *p* \< 0.0001 and 23.6%, OR 5.143, *p* = 0.0156, respectively, versus 5.6%). The percentage of patients who achieved complete mucosal healing in the budesonide foam BID group was approximately twice that in the QD group \[46.4%, OR 3.024, *p* = 0.0097 versus 23.6%\] \[[Figure 2a](#F2){ref-type="fig"}\]. A significant dose-response relationship for achieving complete mucosal healing was found in the two budesonide foam groups \[Cochran-Mantel-Haenszel test, *p* \< 0.0001\]. The subgroup of patients with previous use of 5-ASA enema or suppository in the recent active phase indicated that these patients were treated by 1-g enemas of 5-ASA or by 1-g suppositories of 5-ASA or by 500-mg suppositories of salazosulfapyridine before enrolment, and entered this study because of insufficient effect of these therapies. Based on the subgroup analysis, the percentages of complete mucosal healing in the budesonide foam BID and QD groups of patients with no previous use of a 5-ASA enema or suppository in the recent active phase were significantly greater than those in the placebo foam group \[58.1%, OR 24.867, *p* = 0.0001 and 34.4%, OR 8.354, *p* = 0.0100, respectively, versus 6.1%\]. The percentage of patients who achieved complete mucosal healing in the budesonide foam BID group was significantly higher than that in the QD group \[58.1%, OR 2.977, *p* = 0.0431 versus 34.4%\]. In the subgroup of patients with a previous use of a 5-ASA enema or suppository in the active phase, a greater percentage of complete mucosal healing was observed in the BID budesonide foam group \[32.0%\] compared with 8.7% in the QD group \[OR 4.688, *p* = 0.0774\], or 4.8% in the placebo group \[OR 7.680, *p* = 0.0763\], although a significant difference was not observed \[[Figure 2b](#F2){ref-type="fig"}\].

![Percentages of complete mucosal healing. \[a\] Full analysis set. \[b\] Subgroup analysis of patients with a previous use of 5-ASA enemas or suppositories in the recent active phase. Statistical analyses are performed at a significance level of 0.05 \[two-sided\]. \* Significant difference. BID, twice a day; QD, once daily; 5-ASA, 5-aminosalicylic acid.](eccojc_jjv208_f0002){#F2}

3.3. Clinical remission {#s13}
-----------------------

At Week 6, the percentages of patients achieving clinical remission in the budesonide foam BID and QD groups were significantly greater than that in the placebo foam group \[48.2%, OR 3.674, *p* = 0.0029 and 50.9%, OR 3.994, *[p]{.ul}* = 0.0015, respectively, versus 20.4%\] \[[Figure 3a](#F3){ref-type="fig"}\]. The percentages of clinical remission were generally comparable among all subgroups, regardless of the extent of lesions and previous use of a 5-ASA enema or suppository \[[Figure 3b](#F3){ref-type="fig"}\].

![Percentage of clinical remission. \[a\] Full analysis set. \[b\] Subgroup analysis. Statistical analyses are performed at a significance level of 0.05 \[two-sided\]. \* Significant difference. BID, twice a day; QD, once daily; 5-ASA, 5-aminosalicylic acid.](eccojc_jjv208_f0003){#F3}

3.4. Other endpoints {#s14}
--------------------

The percentages of patients with an endoscopic subscore ≤ 1 in the budesonide foam BID and QD groups were statistically greater than that in the placebo foam group \[76.8%, *p* = 0.0007 and 69.1%, *p* = 0.0139, respectively, versus 46.3%\] \[[Table 2](#T2){ref-type="table"}\]. The percentages of patients with an MMDAI score ≤ 1 in the budesonide foam BID and QD groups were statistically greater than that in the placebo foam group \[50.0%, *p* \< 0.0001 and 38.2%, *p* = 0.0022, respectively, versus 11.1%\]. In both the BID and QD groups, the percentages of elimination of rectal bleeding were higher than that in the placebo group \[[Table 2](#T2){ref-type="table"}, [Figure 4](#F4){ref-type="fig"}\].

###### 

Summary of the efficacy endpoints.

                                            Placebo \[*N* = 54\]   Budesonide foam QD \[*N* = 55\]   Budesonide foam BID \[*N* = 56\]
  ----------------------------------------- ---------------------- --------------------------------- ----------------------------------
  Endoscopic subscore ≤ 1, *n* \[%\]        25 \[46.3\]            38 \[69.1\]                       43 \[76.8\]
  Odds ratio                                                       2.762                             4.333
  *P*-value                                                        0.0139                            0.0007
  MMDAI ≤ 1, *n* \[%\]                      6 \[11.1\]             21 \[38.2\]                       28 \[50.0\]
  Odds ratio                                                       4.966                             8.613
  *P*-value                                                        0.0022                            \<0.0001
  Rectal bleeding subscore = 0, *n* \[%\]                                                            
  Week 2                                    13 \[24.1\]            24 \[43.6\]                       25 \[44.6\]
  Odds ratio                                                       2.497                             2.655
  *P*-value                                                        0.0307                            0.0208
  Week 4                                    15 \[28.3\]            27 \[50.0\]                       35 \[66.0\]
  Odds ratio                                                       2.552                             5.617
  *P*-value                                                        0.0276                            0.0001
  Week 6                                    19 \[37.3\]            38 \[70.4\]                       37 \[69.8\]
  Odds ratio                                                       4.240                             4.393
  *P*-value                                                        0.0010                            0.0008

Statistical analyses were performed at the level of significance of 0.05 \[two-sided\].

MMDAI, Modified Mayo Disease Activity Index; BID, twice a day administration; QD, once daily administration.

![Percentage of patients with a rectal bleeding score of 0 on each day. BID, twice a day; QD, once daily.](eccojc_jjv208_f0004){#F4}

3.5. Safety {#s15}
-----------

All 165 randomised patients were included in the safety analysis set. A summary of adverse events is shown in [Table 3](#T3){ref-type="table"}. The incidence of adverse events was 29.6%, 47.3%, and 67.9% in the placebo, QD, and BID groups, respectively, and the incidence of study drug-related adverse events was 11.1%, 30.9%, and 53.6%, respectively. No serious adverse event was reported. The incidence of adverse events leading to treatment discontinuation was 3.7%, 0%, and 3.6% in the placebo, QD, and BID groups, respectively. Regarding symptoms by potential glucocorticoid effects such as a moon face, flushing, fluid retention, mood changes, insomnia etc., there was no evidence of any increase in patients of symptoms caused by glucocorticoids in either the budesonide foam BID or QD group. Among common adverse events, a decrease in the plasma cortisol level and blood corticotrophin level occurred only in the two budesonide foam groups. The incidence of these adverse events was higher in the BID group than in the QD group. The mean plasma cortisol level also decreased in both groups \[[Figure 5a](#F5){ref-type="fig"}\]. However, in the follow-up survey of 38 patients with a decrease of the plasma cortisol level at Week 6, their plasma cortisol levels returned to the normal level \[≥ 4.0 μg/dl\] after treatment was terminated \[[Figure 5b](#F5){ref-type="fig"}\]. Similar results were shown in the follow-up survey of patients with decreases of their blood corticotrophin levels \[data not shown\].

###### 

Adverse events.

                                                          Placebo \[*N* = 54\]   Budesonide foam QD \[*N* = 55\]   Budesonide foam BID \[*N* = 56\]
  ------------------------------------------------------- ---------------------- --------------------------------- ----------------------------------
  Summary of adverse events, *n* \[%\]                                                                             
   Adverse events                                         16 \[29.6\]            26 \[47.3\]                       38 \[67.9\]
   Study drug-related adverse events                      6 \[11.1\]             17 \[30.9\]                       30 \[53.6\]
   Death                                                  0 \[0.0\]              0 \[0.0\]                         0 \[0.0\]
   Serious adverse events                                 0 \[0.0\]              0 \[0.0\]                         0 \[0.0\]
   Adverse events leading to treatment discontinuation    2 \[3.7\]              0 \[0.0\]                         2 \[3.6\]
  Common adverse events^a^, *n* \[%\]                                                                              
   Infections and infestations                            \-                     \-                                \-
    Nasopharyngitis                                       3 \[5.6\]              6 \[10.9\]                        4 \[7.1\]
   Nervous system disorders                               \-                     \-                                \-
    Headache                                              1 \[1.9\]              \-                                6 \[10.7\]
   Gastrointestinal disorders                             \-                     \-                                \-
    Vomiting                                              \-                     \-                                2 \[3.6\]
    Colitis ulcerative                                    2 \[3.7\]              \-                                1 \[1.8\]
   General disorders and administration site conditions   \-                     \-                                \-
    Pyrexia                                               2 \[3.7\]              2 \[3.6\]                         \-
  Investigations                                          \-                     \-                                \-
    Plasma cortisol decrease                              \-                     12 \[21.8\]                       26 \[46.4\]
    Plasma corticotrophin decrease                        \-                     8 \[14.5\]                        16 \[28.6\]
   Blood creatine phosphokinase increase                  \-                     2 \[3.6\]                         \-

^a^ Defined as an adverse event that occurred in at least two patients in any group.

BID, twice a day administration; QD, once daily administration.

![Morning plasma cortisol levels. \[a\] Morning plasma cortisol levels at baseline and Week 6 in the full analysis set. \[b\] The recovery of plasma cortisol levels at the follow-up visit. Morning plasma cortisol levels at baseline and Week 6, and the follow-up visit of patients with a decrease of plasma cortisol level at Week 6 \[N = 38\]. Data presented are mean and standard deviation. BID, twice a day; QD, once daily.](eccojc_jjv208_f0005){#F5}

3.6. Patients' acceptance {#s16}
-------------------------

Responses to the questionnaires were collected from 164 of 165 patients who were treated with the study drug. The results of the questionnaires are shown in [Table 4](#T4){ref-type="table"}; 95.6% of patients said that handling the device was very easy to usual. The majority of patients answered none to slight about having an unpleasant feeling, retention problem, or flatulence \[82.9%, 95.1%, and 83.6%, respectively\]. Regarding the difficulty in the BID administration, 83.0% of patients answered none to moderate. Of 164 patients, 125 who had experience with other enema preparations answered the same questions from the viewpoint of comparing the foam preparations in this study with other liquid enema preparations. In these patients, a higher percentage of patients answered very easy regarding handling the device \[56.8%\] compared with all patients \[34.1%\]. Furthermore, the percentage of patients in the subgroup \[55.2%\] with experience with other enema preparations, who answered none about having an unpleasant feeling, was higher than that in all patients \[28.0%\].

###### 

Patients' acceptance.

                                                All patients \[*N* = 164\]   Subgroup with experience of other enemas \[*N* = 125\]
  --------------------------------------------- ---------------------------- --------------------------------------------------------
  Handling of device, %                                                      
   Very easy                                    34.1                         56.8
   Easy                                         46.3                         27.2
   Usual                                        15.2                         10.4
   Difficult                                    4.3                          4
   Very difficult                               0                            0.8
   No answer                                    0                            0.8
  Unpleasant feeling, %                                                      
   None                                         28                           55.2
   Slight                                       54.9                         37.6
   Moderate                                     13.4                         3.2
   Severe                                       3                            0.8
   Very severe                                  0.6                          0.8
   No answer                                    0                            2.4
  Retention problem, %                                                       
   None                                         75                           82.4
   Slight                                       20.1                         10.4
   Moderate                                     3                            3.2
   Severe                                       1.2                          0.8
   Very severe                                  0.6                          0
   No answer                                    0                            3.2
  Flatulence, %                                                              
   None                                         47.6                         67.2
   Slight                                       36                           24
   Moderate                                     12.2                         4.8
   Severe                                       4.3                          1.6
   Very severe                                  0                            0
   No answer                                    0                            2.4
  Difficulty of twice daily administration, %                                
   None                                         34.8                         41.6
   Slight                                       30.5                         24
   Moderate                                     17.7                         16.8
   Severe                                       14.6                         12.8
   Very severe                                  2.4                          2.4
   No answer                                    0                            2.4

4. Discussion {#s17}
=============

Previous clinical studies have shown that budesonide foam is effective and well tolerated in the treatment of patients with active, mild to moderate UC.^[@CIT0010],[@CIT0011]^ However, a few studies have focused on BID administration for 6 weeks or the therapeutic potential to induce complete mucosal healing, because budesonide foam has been commonly used as QD administration in Europe and BID administration for only 2 weeks in the USA. Our study was the first trial to evaluate the efficacy and safety of BID budesonide foam for 6 weeks in terms of achieving complete mucosal healing. A recent study indicated that 55.8% of patients receiving budesonide foam BID for 2 weeks and then QD for 4 weeks achieved an endoscopic subscore of 0 or 1, whereas 76.8% of patients with an endoscopic subscore ≤ 1 in the budesonide foam BID group and 46.4% of patients receiving budesonide foam BID for 6 weeks achieved complete mucosal healing \[an endoscopic subscore of 0\] in our study. Thus, budesonide foam BID for 6 weeks maybe useful for achieving complete mucosal healing in patients with UC.

In previous studies, it has been shown that there was no significant difference in the clinical remission rates between QD and BID administration of a 2-mg budesonide enema.^[@CIT0012]^ On the basis of this study, the recommended dose of a budesonide enema or budesonide foam was QD administration.^[@CIT0010],[@CIT0012]^ Meanwhile, a previous dose-ranging study suggested that a \> 2-mg dosing of budesonide enema was possibly more effective in sigmoidoscopic inflammation than a 2-mg dosing.^[@CIT0013]^ Consistent with these reports, our study suggested that BID administration of budesonide 2-mg foam \[4mg/day in total\] showed the potential benefit compared with QD administration \[2mg/day\] in terms of improving colonic inflammation. This difference was not observed when we focused on clinical remission only. On the other hand, in an uncontrolled open-label trial, a total of 12 patients with mild to moderate active distal UC applied a single rectal dose of 99mTc-labelled budesonide 2-mg foam for gamma scintigraphical examination to determine extent of foam distribution within the colon.^[@CIT0014]^ The scintigraphy data from this study demonstrated that the greater part of drug cleared in rectum within only 6h, suggesting that twice-daily administration could extend the exposure time of budesonide to the rectum. Thus, the better effect of BID administration of budesonide 2-mg foam was considered not only due to the higher dose of budesonide but also to the twice daily administration.

Our study showed that BID administration of budesonide foam induced complete mucosal healing in approximately half of UC patients. A previous clinical trial in mild to moderate UC patients has reported the percentages of patients with complete mucosal healing after treatment by oral 5-ASA preparations. After treatment for 8 weeks, 32.0% of patients treated with 2.4g of oral 5-ASA and 32.3% of patients treated with 4.8g of oral 5-ASA achieved complete mucosal healing.^[@CIT0009]^ In a randomised clinical trial of 5-ASA suppositories, the percentages of patients with complete mucosal healing were 29.0% in QD 5-ASA suppository therapy for 4 weeks.^[@CIT0015]^ However, in our study, 46.4% of patients achieved complete mucosal healing after BID budesonide foam therapy for 6 weeks. Whereas the percentages of clinical remission were generally comparable among all subgroups, the percentage of complete mucosal healing was potentially influenced by the MMDAI and the history of previous medication by 5-ASA enemas or suppositories in the recent active phase. The percentage of complete mucosal healing in the subgroup of patients with MMDAI of 6--8 \[32.3%, 10 of 31\] was apparently lower than that in the subgroup of patients with MMDAI of 3--5 \[64.0%, 16 of 25\], suggesting that budesonide foam is more effective in inducing complete mucosal healing in patients with mild UC than in patients with moderate UC. The subgroup of patients with previous use of 5-ASA enema or suppository in the recent active phase was considered to contain patients with insufficient effects or intolerant of 5-ASA enemas or suppositories. Remarkably, 58.1% of patients achieved complete mucosal healing in the subgroup of patients without previous use of 5-ASA enema or suppository in the recent active phase. Furthermore, even in the subgroup of patients with a previous use of 5-ASA enema or suppository in the preent active phase, 32.0% of patients treated with BID budesonide foam achieved complete mucosal healing. This result suggests that BID budesonide foam was a good therapeutic option for UC patients with unacceptable or ineffective experience of 5-ASA enema or suppository use. The proximal extent of the colonic mucosal inflammation in UC patients varies among individuals, but it usually involves a lesion in the area from the sigmoid colon to the rectum because inflammation often extends distal to proximally in UC patients.^[@CIT0016],[@CIT0017],[@CIT0018]^ Thus, complete mucosal healing of distal lesion is an important therapeutic target for a large majority of UC patients.

Our study was the first trial to evaluate the efficacy of budesonide foam to induce clinical remission in Japanese UC patients. On the basis of our results, both QD and BID dosages of budesonide foam were confirmed to be significantly effective compared with placebo in terms of clinical remission after 6 weeks of treatment. In a previous study in patients with active ulcerative proctitis or proctosigmoiditis, the clinical remission rates \[defined as disease activity index ≤ 3\] for QD 6-week treatment of budesonide 2-mg foam and budesonide 2-mg enema were 57% and 64%, respectively.^[@CIT0010]^ In two recent randomiszed, placebo-controlled phase 3 studies in the USA, the efficacy and safety of budesonide 2-mg foam treatment BID for 2 weeks and then QD for 4 weeks were evaluated in patients with active, mild to moderate ulcerative proctitis or proctosigmoiditis. In these studies, the percentages of patients with clinical remission \[defined as a rectal bleeding subscore of 0, endoscopic subscore ≤ 1, and the decrease of ≥ 0 in the stool frequency subscore from baseline\] for budesonide 2-mg foam and placebo foam were 38.3% and 25.8%, respectively \[study 1\], and 44.0% and 22.4%, respectively \[study 2\].^[@CIT0011]^ Although there are some differences in the definition of clinical remission between studies, the clinical remission rate in Japanese UC patients treated with budesonide foam for 6 weeks was considered generally consistent with previous reports. In the subgroup analysis, budesonide foam was confirmed to be effective in patients with a previous use of 5-ASA enemas or suppositories in the present active phase as well as patients with no previous use of them. Rectal corticosteroids are often used for patients with intolerant or insufficient response to 5-ASA enema or suppository.^[@CIT0019]^ Thus, our results suggested the great benefit of budesonide foam for inducing clinical remission for these patients as well.

The assessment of safety and patient acceptance showed that budesonide foam is well tolerated in patients with QD administration and in those with BID administration. No serious adverse event was reported in any group. Although a decrease of the plasma cortisol and plasma corticotrophin levels was reported in patients in the budesonide foam groups, all recovered to normal levels after completing treatment. There was no evidence of any other increase of adverse event caused by glucocorticoids in either of the budesonide foam groups. The safety profile in this study was consistent with the worldwide experience of budesonide foam and oral budesonide formulation for UC.^[@CIT0011],[@CIT0020],[@CIT0021]^ These results indicated that BID and QD budesonide foam were well tolerated.

Foam preparation is more convenient to administer and is better tolerated compared with a liquid enema. Because foam formulations can remain in contact with the mucosa for a long time, foam preparations are easier to maintain without leakage of the drug. Furthermore, the administration of foam preparation can be easily performed in the standing position, whereas liquid enema preparations must be administered with patients lying down. Actually, it has been reported that 84% of UC patients preferred foam preparations whereas enemas were only preferred by 6%, in a randomised study from Europe, demonstrating that foam preparation resolves problems related to liquid enema preparations.^[@CIT0010]^ In this study, a direct comparison between budesonide foam and other enemas was not performed. However, the results of our questionnaires were generally consistent with those of patients using budesonide foam, in a previous report.^[@CIT0010]^ Other enemas approved in Japan were commonly used by the QD administration. Hence, we were concerned that BID administration might be considered unacceptable by patients who were familiar with other enemas. Nevertheless, \> 65% of patients answered none or slight to the questionnaire regarding difficulty with BID administration, regardless of their experience with other enemas. This result supports the conclusion that budesonide foam was generally accepted by patients even if they were required to receive it BID for 6 weeks.

In summary, our new results suggest that BID administration of budesonide foam effectively induced complete mucosal healing. BID administration of budesonide foam was not associated with any serious problems related to safety and application. BID budesonide foam has the possibility to be a therapeutic option for achieving complete mucosal healing in patients with mild to moderate UC.
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